Preparation of Folate Targeted Pullulan Acetate Nanoparticles and Cell Uptake in vitro

Abstract

Abstract:

Pullulan acetate(PA) was synthesized via the reaction of pullulan with acetic anhydride. Folate was coupled to PA by N,N′-dicyclohexylcarbodiimide(DCC) and 4-dimethylamino-pyridine(DMAP) mediated ester formation. The products were characterized with ¹H NMR spectroscopy and X-ray diffraction(XRD). The solvent diffusion method was used to prepare epirubicin(EPI) loaded nanoparticles. The morphology of nanoparticles was sphere measured by transmission electron microscopy(TEM), and the size of nanoparticles was 200—500 nm determined by dynamic light scattering(DLS). The results revealed that drug loading efficiencies and diameters of nanoparticles increased as the drug/materials ratio increasing. The EPI release rate in vitro was measured using a dialysis tube. Cellular uptake extents of PA and FPA were evaluated with confocal microscopy. The result show more fluorescently labeled cells can be clearly visualized in the absence of folate in the medium than presence of 1 mmol/L folate when KB cell incubated with FPA/EPI nanoparticles, suggesting FPA/EPI nanoparticles are endocytosed in a folate receptor-mediated manner.

Key words: Folate receptor, Cancer targeted, Pullulan acetate, Nanoparticle, Solvent diffusion method

TrendMD:

ZHANG Hui-Zhu*, ZHANG Qi-Qing. Preparation of Folate Targeted Pullulan Acetate Nanoparticles and Cell Uptake in vitro[J]. Chem. J. Chinese Universities, 2009, 30(6): 1146.

References

[1]Asak C. A.. Annu. Rev. Nutr.[J], 1996, 16: 501—21
[2]Ross J. F., Chaudhuri P. K.. Cancer[J], 1994, 73: 2432—2443
[3]Wu J., Liu Q., Lee R. J.. Int. J. Pharm.[J], 2006, 316: 148—153
[4]Saul J. M., Annapragada A., Natarajan J. V.. J. Controlled Release[J], 2003, 92: 49—67
[5]Turk M. J., Reddy J. A., Chmielewski J. A., et al.. Biochim. Biophy. Acta[J], 2002, 1559: 56—68
[6]Liu S. Q., Wiradharma N., Gao S. J.. Biomaterials[J], 2007, 28: 1423—1433
[7]Licciardi M., Giammona G., Du J. Z., et al.. Polymer[J], 2006, 47: 2946—2955
[8]Zhao H. Z., Yung L. Y. L.. Int. J. Pharm.[J], 2008, 349: 256—268
[9]Schroeder J. E., Shweky I., Shmeeda H., et al.. J. Controlled Release[J], 2007, 124: 28—34
[10]Moses O. O., Russell J. M.. Int. J. Pharm.[J], 2003, 251: 85—97
[11]Goren D., Horowitz A. T., Tzemach D., et al.. Clin. Cancer Res.[J], 2000, 6: 1949—1957
[12]Kimoto T., Shibuya T., Shiobara S.. Food Chem. Toxicol.[J], 1997, 35: 323—329
[13]Kazunari A., Seiichi K., Shozo S., et al.. J. Controlled Release[J], 1998, 54: 313—320
[14]Jeong Y., Na H. S., Oh J. S., et al.. Int. J. Pharm.[J], 2006, 322: 154—160
[15]Na K., Lee T. B., Park K. H., et al.. Eur. J. Pharm. Sci.[J], 2003, 18: 165—173
[16]Motozato Y., Ihara H., Tomoda T., et al.. J. Chromatography[J], 1986, 355: 434—437
[17]Park E. K., Lee S. B., Lee Y. M.. Biomaterials[J], 2005, 26: 1053—1061
[18]Naozumi T., Mitsuhiro S.. Carbohyd. Polym.[J], 2006, 63: 476—481
[19]Bilati1 U., All′emann E., Doelker E.. Eur. J. Pharm. Sci.[J], 2005, 24: 67—75
[20]Rejman J., Oberle V., Zuhorn I. S., et al.. Biochem. J.[J], 2004, 377: 159—169
[21]Jayanth P., Vinod L.. Adv. Drug Deliv. Rev.[J], 2003, 55: 329—347
[22]Khalil I. A., Kogure H. K., Akita H., et al.. Pharmacol. Rev.[J], 2006, 58: 32—45